DNA diagnostics of genetic diseases increasingly shifts towards utilization of commercial assays. Cystic fibrosis (CF)-related DNA diagnostics were used as a model for a pilot survey of the variability in the utilization of qualitative CE-marked in vitro diagnostic (IVD) assays and the scale of their modification by end users. A structured questionnaire, developed in the context of the EuroGentest project, was distributed within the frame of the 2005 annual CF external quality assessment (EQA) scheme. Its aim was to evaluate the variability in the use of different CE-marked IVD assays in routine CF DNA diagnostics. Survey results were analysed and sequentially discussed with respective users and/or manufacturers. In total, 125 responses from EQA scheme participants were received. Almost half of the respondents modified manufacturer-recommended protocols. They also reported sporadic and/or recurrent problems with assay performance and genotyping of particular alleles. Nonetheless, only half of the respondents performed in-house verification before the implementation of the assay in clinical diagnostics and/or after modification of the recommended protocol. Results of this survey substantiate the importance of guidelines for proper verification of CE-marked IVD assays in DNA diagnostics, using CF as a model.

Department of Biology and Medical Genetics Charles University Prague 2nd School of Medicine and University Hospital Motol Prague Czech Republic

Eur J Hum Genet. 2009 Apr;17(4):403-5. doi: 10.1038/ejhg.2008.229. PubMed

See more in PubMed

Dequeker E, Cuppens H, Dodge H, et al. Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis. Eur J Hum Genet. 2000. pp. S2–S24. PubMed

Dequeker E, Cassiman JJ. Genetic testing and quality control in diagnostic laboratories. Nat Genet. 2000;25:259–260. PubMed

Girodon-Boulandet E, Cazeneuve C, Goossens M. Screening Practices for Mutations in the CFTR Gene ABCC7. Hum Mutat. 2000;15:135–149. PubMed

Cassiman JJ. Research network: EuroGentest – a European Network of Excellence aimed at harmonizing genetic testing services. Eur J Hum Genet. 2005;13:1103–1105. PubMed

Directive 98/79/EC of the European Parliament and of the Council The European Parliament and the Council of the European Union 1998, , http://www.ivd-ce.com/ivd.pdf (Accessed October 2007).

Dequeker E, Ramsden S, Grody WW, Stenyel TT, Barton DE. Quality control in molecular genetic testing. Nat Rev Genet. 2001;2:717–723. PubMed

Prence E. A practical guide for the validation of genetic tests. Genet Test. 1999;3:201–205. PubMed

Ramsden SC, Deans Z, Robinson DO, et al. Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland. Genet Test. 2006;10:147–156. PubMed

OECD Guidelines for Quality Assurance in Molecular Genetic Testing, OECD 2007 , http://www.cfnetwork.be/doc/QAGuidelineseng.pdf (Accessed May 2007).

Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry

The future of cystic fibrosis care: a global perspective